Novartis (NOVN) Receives CHF 87.85 Consensus Price Target from Brokerages

Novartis (VTX:NOVN) has earned an average recommendation of “Hold” from the twenty research firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is CHF 87.85.

A number of equities analysts have weighed in on NOVN shares. Barclays set a CHF 80 target price on shares of Novartis and gave the company a “sell” rating in a research note on Tuesday, February 20th. Jefferies Group set a CHF 95 target price on shares of Novartis and gave the company a “buy” rating in a research note on Monday, February 26th. Goldman Sachs set a CHF 90 target price on shares of Novartis and gave the company a “neutral” rating in a research note on Friday, March 2nd. Baader Bank set a CHF 95 target price on shares of Novartis and gave the company a “buy” rating in a research note on Friday, February 16th. Finally, Societe Generale set a CHF 95 target price on shares of Novartis and gave the company a “buy” rating in a research note on Wednesday, February 21st.

NOVN traded up CHF 0.34 on Monday, hitting CHF 78.38. The company had a trading volume of 11,210,000 shares, compared to its average volume of 5,980,000. Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply